Update: May 23, 2022 11:57 a.m. STI
Mountain View (California) [US]/Pune (Maharashtra) [India]May 23 (ANI/PRNewswire): Today marks the start of a new era in cancer diagnostics and precision medicine with the coming together of two leading organizations, Silicon-based leader Crosscope Inc. Valley and provider of Vendor Agnostic AI-enabled digital pathology platform, and Farcast Bioscience LLC, a Florida-based company.
Farcast has developed a unique and differentiated human tumor histoculture platform that can preserve the entire architecture of the human tumor microenvironment.
The two companies will work together for the prospective evaluation of OrionAI™ – a breakthrough AI-based diagnostic assistant for the histological examination of a variety of solid tumors, starting with squamous cell carcinoma cancer of the head and of the neck (HNSCC).
HNSCC is the most prevalent cancer in India and the two companies have decided to enter into a collaboration to fight a disease which poses a unique health challenge for India.
This partnership will help researchers collaborate, centrally review, facilitate image training, visualization and analysis, and at the same time be used to improve the assessment of standard pathological features.
AI and machine learning have shown promising results in several areas of health. The application of Crosscope’s proprietary technology and algorithm holds tremendous promise in tackling the global burden of cancer.
There is a huge supply gap in the number of trained pathologists required in the way workflows are set up across the world. By increasing the capacity of pathologists, Crosscope and Farcast aim to accelerate the speed of diagnosis by dramatically reducing turnaround times (TATs) and reducing the rate of diagnostic errors by leveraging the digitization of pathology.
Digital pathology uses predefined algorithms to generate consistent and faster histopathological analysis which has brought significant advances in the quantification and identification of different markers capable of predicting disease progression, patient prognosis and therapeutic response.
The combination of digital pathology with other emerging technologies, such as artificial intelligence and machine learning, shows great promise for identifying predictive biomarkers for several types of cancer.
The main objective of this collaboration is to evaluate the ability of Crosscope’s state-of-the-art deep learning technology to detect and quantify key features of tumor pathology from digitized H&E slides and to study their correlation and accuracy relative to the assessment of trained pathologists.
This will further showcase the performance of Crosscope’s algorithms which are adaptable to independent test cohorts, images and variable slide tissue content, making it a flexible, versatile and adaptable method in clinical and research settings. .
“OrionAI™, based on deep learning, is dedicated to the precise detection and evaluation of clinically relevant findings in digitized cancer biopsy slides. This collaboration will enhance the power of digital transformation by accelerating drug discovery and driving new breakthroughs that will contribute to better cancer diagnosis. We are excited to work with Mohit and his team at Farcast Biosciences to bring advanced tools for precision diagnostics,” said Dr. Jayendra Shinde, CEO of Crosscope.
Farcast Biosciences CSO Satish Sankaran, PhD said, “Farcast TiME (Antitumor Immune Microenvironment) is a human tumor microenvironment platform that has demonstrated preservation of all elements of the human tumor microenvironment for up to 72 hours.
The digitization and assessment of AI-based histopathology will go a long way to improving the speed, efficiency, and robustness of our pathology workflows. »
Mohit Malhotra, CEO of Farcast Biosciences, added, “Histopathology is one of the pillars of our multi-dimensional test system. In our work with the world’s leading biotech companies, this collaboration could help deepen our clients’ insights, leading to more informed choices about their pipeline candidates.
Farcast Biosciences’ unique and proprietary technology uses fresh human tumor samples cultured in a proven system that recreates the TiME (tumor immune microenvironment) ex vivo.
The culture system maintains morphology and viability while retaining native tumor architecture and immune components to enable assessment of tumor response to drug therapy.
Farcast works with IRB approved cancer centers to access new tumor samples from informed donors after obtaining their consent. Farcast TiME can assess therapeutic response in many classes of drugs, including bispecific antibodies, monoclonal antibodies, small molecules, and oncolytic viruses over a relatively short period of time.
Farcast offers a wide range of kinetic and endpoint assays for the multidimensional analysis of mechanistic action and impact of therapeutic agents on the tumor microenvironment in a cost-effective manner.
Contact us | Communications Manager | Email: [email protected]
For more information go to: https://www.farcastbio.com/ or connect to Linkedin
Crossscope; abbreviated as “Computational Microscope” is a medical AI software company whose mission is to radically transform patient care by unleashing the power of AI.
The Company’s Crosscope Dx software is a digital pathology platform that facilitates the deployment of scalable artificial intelligence and computational pathology tools to equip pathology laboratories with precision diagnostics.
Crosscope’s team of engineers, data scientists, and pathologists develops a unique platform and AI approach to deliver efficient pathology workflows for increased diagnostic accuracy and productivity.
Contact us | Press officer | Email: [email protected]
For more information visit: www.crosscope.com or connect on LinkedIn and Twitter
This story is provided by PRNewswire. ANI will not be responsible for the content of this article. (ANI/PRNewswire)